AlphAIAlphAI — Financial news for AI agents
foodbusinessmea.comOCT 92 min read$TLRY

Tilray Brands revenue rises 20% in Q1 2027

Tilray Brands reported a 20% revenue increase to $257.1M in Q1 2027, driven by beverage sales. Gross profit rose 35% to $77.5M. Beverage revenue grew 82% to $101.5M, while cannabis revenue declined. The company reported a net loss of $40M but reduced debt by $42M. Tilray reaffirmed its adjusted EBITDA guidance of $68M-$75M for the fiscal year.

Original reporting
foodbusinessmea.com
Published Oct 9, 2026, 10:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tilray Brands revenue rises 20% in Q1 2027 — source image
Source · foodbusinessmea.com
Decision brief

The 30-second read

$TLRYNeutralMed
01

Why it matters

The earnings release provides fresh data on revenue growth, margin expansion, and cash position, offering traders a basis to reassess valuation.

02

Market read

Tilray's earnings update may influence cannabis and beverage sector sentiment, but broader market impact is limited.

03

What to watch

Cost reductions at international cultivation sites and BrewDog's profitability may improve future cash flow.

Relevance 7/10Novelty 7/10Timing: after-hours earnings release

Background

Tilray Brands, a cannabis‑beverage‑wellness company, released its Q1 FY2027 results, highlighting strong beverage sales after acquiring BrewDog.

Company-level read

Ticker impact

$TLRYNeutralHigh confidence
Context

Tilray Brands reported Q1 FY2027 revenue up 20% to $257.1M, but posted a $40M net loss and reaffirmed FY adjusted EBITDA guidance.

Expected impact

likely modest downside as investors weigh higher revenue against continued net loss and flat guidance

Evidence & confidence

Revenue growth and margin improvement are positive, but the sizable net loss and no guidance lift suggest limited bullish pressure.

Market effects

Sector

Cannabis and beverage segments see revenue boost, potentially supporting peers with similar product mixes.

Regional

North American cannabis market may see modest re‑rating as Tilray improves margins.

Global

Limited; primarily impacts Tilray and its immediate sector.

Counterpoint

What could challenge this read

Despite revenue growth, the persistent net loss and unchanged guidance could signal deeper profitability challenges.

Key entities

  • Company
    Tilray Brands

    US‑listed cannabis and beverage company (ticker TLRY).

  • Company
    BrewDog

    Acquired beverage brand now contributing to Tilray's revenue growth.

Read at source← All news

StoryTilray reports strong beverage-led Q1 growth but reaffirms outlook amid cannabis decline

Also covered by

4 outlets

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min